The Senate takes up its version of the health reform bill, creating an opportune moment to revisit what the goals of reform are and whether this bill will actually widen access, lower cost or improve quality. The answer is likely not.
Read More
The CBO released a brief report looking at the potential impact of various changes in federal policies on research and development spending for drugs. Current and future policies are not likely to encourage more R & D.
The Office of Inspector General issues a work plan every year which gives guidance on potential areas of mismanagement, fraud and abuse in federal programs. This year’s plan reveals continuing focus on hospital and nursing home payments and drug reimbursement.
The Congressional Budget Office releases its preliminary analysis of the House health care reform bill, finding it will expand coverage to most legal citizens and reduce the deficit.